Estee Lauder Companies Inc vs GeneDx Holdings Corp — how do they compare? Estee Lauder Companies Inc trades at $88.39 (market cap $31.76B), while GeneDx Holdings Corp trades at $81.63 (market cap $2.44B). The key difference: Estee Lauder Companies Inc is far larger — about 13× GeneDx Holdings Corp's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| EL | WGS | |
|---|---|---|
Market Cap | $31.76B | $2.44B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $167.51 |
52-Week Low | $67.23 | $34.51 |
Enterprise Value | $37.93B | $2.48B |
Dividend Yield | 1.59% | — |
Signals from Pluang's Aura AI — not financial advice
EL trades at $88.56, up 1.57% today, with a bullish technical trend and strong recent earnings beats. The stock shows robust gross margins of 74.71% but faces profitability challenges with a negative net income margin. Analyst consensus is mixed with a $91.67 price target, while recent news highlights new product launches and institutional accumulation.
Outlook remains cautiously optimistic given earnings momentum and brand strength, but high valuation multiples and inconsistent cash flow pose risks. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity in the beauty sector.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →